Abstract
The countries of Western Europe represent a total market of over 403 million
people and a combined GDP of US$18.1 trillion in 2008. Each country report in
this regional collection provides a comprehensive analysis of the
pharmaceutical market, including five-year market forecasts. For each country
you will receive 4 completely updated reports sent quarterly, plus
comprehensive report sent annually.
The countries of Western Europe represent a total market of over 403 million
people and a combined GDP of US$18.1 trillion in 2007.
The 11 main Western European markets for pharmaceuticals are wealthy and
mature. Is there any point in manufacturers trying to break into markets they
are not already servicing, and, if yes, where? If they are already operating
in the region, what are the prospects for growth and what operating
environment will they face in the future?
Valuable markets...
News stories chronicle the pressures and problems facing governments trying to
expand or maintain health provision in a costconstrained world. But one fact
remains. The countries covered by this report represented a total
pharmaceutical market value of US$239.1 billion in 2008. We forecast this
figure will grow by US$78.6 billion over the next five years to US$317.7
billion!
...with cost pressures
All health funders are experiencing difficulties in meeting the demands on
modern health systems. Pressures arise from many quarters including:
- The cost of current branded medicines which is leading to accelerated
growth in generic usage in key markets such as Spain and France
- The often high cost of new therapies which provide marginal therapeutic
benefit
- An ageing population needing longer and more intensive medical treatments
- Unplanned population increase due to immigration and an influx of migrant
workers
These reports analyse the issues
The Outlook for Pharmaceutical Markets in Western Europe to 2013 is a unique
collection of management reports from Espicom Business Intelligence. Each
report provides individual and highly-detailed analysis of each market,
looking at the key regulatory, political, economic and corporate developments
in the wider context of market structure, service and access. The reports are
available individually, or as a discounted collection, and prices include 4
completely updated reports sent quarterly, plus comprehensive report sent
annually. There are over 60 markets covered in the worldwide series.
11 Key Markets Covered!
- Austria
- Belgium
- France
- Germany
- Ireland
- Italy
- Netherlands
- Portugal
- Spain
- Switzerland
- United Kingdom
FOR EVERY MARKET, SENT QUARTERLY
MARKET OUTLOOK
- Current market size
- Unique 5-Year market projections to 2013
- Market outlook
- Comment & rating, covering 8 key areas such as use of generic drugs,
intellectual property, pricing and the health systems
- Market structure
- Statistical data on imports and exports
- Market developments, covering recent and impending developments with
respect to key issues such as regulation, health facilities, funding and
government policy
- Key national data projections
FOR EVERY MARKET, SENT ANNUALLY
BACKGROUND DATA
- Population data, including growth trends and age structure
- Demographic indicators detailing principal causes of death and morbidity
HEALTHCARE SYSTEM
- Organisation & administration
- Health expenditure
- - Expenditure by source of funding and type
- Hospital services
- - Hospital data such as beds by type, region, specialty, patient
admissions and surgical procedures
- Outpatient care
- Medical personnel
- - Data on healthcare professionals covering such areas as doctors by
specialty, nursing staff and dentists
ACCESSING THE PHARMA MARKET
- Regulatory environment
- Distribution guide and trade fair information
- Domestic production
- Producers
View Cart
